Home
HelpTest Code KI67B Ki-67(MIB-1), Breast, Quantitative Immunohistochemistry, Automated
Reporting Name
Ki67 Breast IHC AutomatedUseful For
Determining proliferation of tumor cells in paraffin-embedded tissue blocks from patients diagnosed with breast carcinoma
Reflex Tests
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| KIBM | Ki67 Breast IHC Manual | No | No |
Testing Algorithm
Cases that are not able to be scanned for automated analysis will be changed to the manual process for analysis.
Method Name
Immunohistochemistry, Automated Quantitation
Performing Laboratory
Mayo Clinic Laboratories in Rochester
Specimen Type
SpecialOrdering Guidance
Ki-67 immunohistochemistry testing on intracystic papillary carcinoma and solid papillary carcinoma, without clearly stating invasive carcinoma, is not appropriate and will be canceled without processing.
If ordering for diagnostic purposes, order PATHC / Pathology Consultation and request the stain.
Shipping Instructions
Attach the green pathology address label included in the kit to the outside of the transport container.
Necessary Information
1. Pathologist's name, address, and phone number are required.
2. Include accompanying pathology report stating the final diagnosis. If not available, a preliminary diagnosis is acceptable only if it refers to invasive or metastatic breast carcinoma.
Specimen Required
Supplies: Pathology Packaging Kit (T554)
Specimen Type: Preferred: Formalin-fixed, paraffin-embedded tissue block containing invasive or metastatic breast carcinoma
Acceptable: 2 Unstained sections, containing invasive or metastatic breast carcinoma, on charged slides cut at 4 microns less than 1 month ago. Tissue on the slides should have been fixed in 10% neutral buffered formalin. Also send one hematoxylin and eosin-stained slide if possible.
Submission Container/Tube: Pathology Packaging Kit
Collection Instructions: Submit paraffin-embedded invasive or metastatic breast carcinoma tissue.
Additional Information: Paraffin block will be returned with the final report.
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Special | Ambient (preferred) | ||
| Refrigerated | |||
Reject Due To
No specimen should be rejected.Reference Values
Varies by tumor type; values reported from 0% to 100%
Day(s) Performed
Monday through Friday
CPT Code Information
88361
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| KI67B | Ki67 Breast IHC Automated | 85330-9 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 70995 | Interpretation | 85330-9 |
| 70996 | Participated in the Interpretation | No LOINC Needed |
| 70997 | Report electronically signed by | 19139-5 |
| 70999 | Material Received | 81178-6 |
| MA023 | Tumor type | 44638-5 |
| MA024 | Tumor classification | 21918-8 |
| 71627 | Disclaimer | 62364-5 |
| 71841 | Case Number | 80398-1 |
Forms
If not ordering electronically, complete, print, and send 1 of the following forms with the specimen:
-Oncology Test Request (T729)
-Immunohistochemical (IHC)/In Situ Hybridization (ISH) Stains Request (T763)
Secondary ID
70588Disease States
- Breast cancer
Clinical Information
Ki-67 (MIB-1 clone) is a monoclonal antibody that reacts with cells undergoing DNA synthesis by binding to the Ki-67 antigen, a marker known to be expressed only in proliferating cells. By measuring the amount of tumor cells expressing Ki-67, an estimate of DNA synthesis can be determined. Studies suggest that Ki-67 (MIB-1) analysis of paraffin-embedded tissue specimens may provide useful prognostic and predictive information in various tumor types.
Interpretation
Results will be reported as a percentage of tumor cells staining positive for Ki-67 (MIB-1). Quantitative Ki-67 (MIB-1) results should be interpreted within the clinical context for which the test was ordered.
The scoring method using Aiforia artificial intelligence for image analysis was developed and validated in the Biomarker and Image Analysis Laboratory, Department of Laboratory Medicine and Pathology, Mayo Clinic (see Method Description).
Cautions
The paraffin block analyzed must be representative of the patient's tumor.
Test results should be interpreted in the context of clinical findings and other laboratory data.
Clinical Reference
1. Urruticoechea A, Smith IE, Dowsett M: Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 2005 Oct 1;23(28):7212-7220
2. de Azambuja E, Cardoso F, de Castro G, et al: Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer 2007 May 21;96(10):1504-1513
3. Nielsen TO, Leung SCY, Rimm DL, et al: Assessment of Ki67 in breast cancer: updated recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst. 2021 Jul 1;113(7):808-819. doi: 10.1093/jnci/djaa201
4. Zhang A, Wang X, Fan C, et al: The role of Ki67 in evaluating neoadjuvant endocrine therapy of hormone receptor-positive breast cancer. Front. Endocrinol. 2021 Nov 3;12:687244
5. Polewski MD, Nielsen GB, Gu Y, et al: A standardized investigational Ki-67 immunohistochemistry assay used to assess high-risk early breast cancer patients in the monarchE Phase3 Clinical Study identifies a population with greater risk of disease recurrence when treated with endocrine therapy alone. Appl Immunohistochem Mol Morphol. 2022 Apr 1;30(4):237-245. doi: 10.1097/PAI.0000000000001009
Method Description
A 4 micron-thick section is cut from the paraffin block. The section is stained with an immunoperoxidase method using the monoclonal antibody Ki-67 (MIB-1 clone). This is the paraffin nuclear epitope to the Ki-67 antigen. Any nucleus that has an antigen-antibody complex will cause the bright-field, brown chromogen, diaminobenzidine (DAB), to precipitate onto it. All nuclei, both DAB positive and negative, are counterstained with diluted hematoxylin.
Ki-67 (MIB-1)-stained slides are scanned using the Leica Aperio GT450 digital scanner. The captured digital image is analyzed in Aiforia by an artificial intelligence algorithm. The Aiforia software renders a percentage of positive-staining tumor nuclei. A technologist reviews the analyzed digital image and ensures at least 80% of the total invasive or metastatic cancer is analyzed appropriately. The Aiforia data and corresponding slide are reviewed by a pathologist for final interpretation.(Unpublished Mayo method)